Magued Rizkalla Hanna, MD
Internal Medicine · Portsmouth, NHNPI 1538259502
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 60.9% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $17,132 and has fallen 91.2% since, to $1,506 in 2025. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $53.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$16K
- Pfizer$1K
- Acadia Pharmaceuticals Inc$1K
- Novo Nordisk$860
- Sunovion Pharmaceuticals Inc.$811
- Bayer$585
- plus $6K from 36 others
What the payments were for
- Speaking & faculty fees$12,61749%
- Travel & lodging$1,5616%
- Food & beverage$11,37744%
- Education$3231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,878 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 496 | $132,380 |
| VelphoroSucroferric Oxyhydroxide | 31 | $41,574 |
| XifaxanRifaximin | 27 | $37,274 |
| MyrbetriqMirabegron | 99 | $27,977 |
| TradjentaLinagliptin | 107 | $27,045 |
| OzempicSemaglutide | 18 | $24,440 |
| XareltoRivaroxaban | 72 | $18,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $17,842 |
| JanuviaSitagliptin Phosphate | 55 | $16,051 |
| Memantine Hcl | 200 | $12,162 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,083 |
| Atorvastatin Calcium | 656 | $10,877 |
| XiidraLifitegrast | 12 | $8,941 |
| FarxigaDapagliflozin Propanediol | 18 | $8,735 |
| Sevelamer Hcl | 15 | $8,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $1,019 | $139,962520 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy | $16 | $40,42192 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $78 | $37,27427 claims |
| Astellas Pharma US IncMyrbetriq | $382 | $27,97799 claims |
| Boehringer IngelheimTradjenta | $34 | $27,045107 claims |
| Novo NordiskOzempic | $860 | $24,44018 claims |
| Johnson & JohnsonXarelto | $15,769 | $18,51072 claims |
| MerckJanuvia | $468 | $16,05155 claims |
| AstraZenecaFarxiga, Brilinta | $190 | $14,52243 claims |
| AbbVieRestasis | $169 | $7,90718 claims |
| NovartisEntresto | $188 | $5,02415 claims |
| Lilly USA, LLCOlanzapine | $377 | $3,54093 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Portsmouth
- Brian HyettPortsmouth$185K
- Katelyn HansonPortsmouth$1K
- Thomas ClairmontPortsmouth$791
- Myhanh NguyenPortsmouth$620
- Donald RainoneLondonderry$1.9M
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
- William MonacoLebanon$97K
- Kevin PhoNashua$40K
- Mary McGowanLebanon$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.